Lipid changes during endocrine therapy in early-stage breast cancer patients: A real-world study

被引:0
作者
Yuechong Li
Zixi Deng
Yingjiao Wang
Songjie Shen
机构
[1] Peking Union Medical College Hospital,Department of Breast Surgery
[2] Peking Union Medical College,undefined
[3] Chinese Academy of Medical Sciences,undefined
来源
Lipids in Health and Disease | / 23卷
关键词
Lipid profile; Breast cancer; Endocrine therapy; Toremifene; Aromatase inhibitors;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 177 条
[1]  
Sung H(2021)Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries CA Cancer J Clin 71 209-49
[2]  
Ferlay J(2016)Cancer statistics in China, 2015 CA Cancer J Clin 66 115-32
[3]  
Siegel RL(2013)EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer Ann Oncol 24 640-7
[4]  
Laversanne M(1999)Risks versus benefits in the clinical application of aromatase inhibitors Endocr Relat Cancer 6 325-32
[5]  
Soerjomataram I(2017)The alterations of serum FGF-21 levels, metabolic and body composition in early breast cancer patients receiving adjuvant endocrine therapy Cancer Biomark 18 441-9
[6]  
Jemal A(2017)The protective role of estrogen and estrogen receptors in cardiovascular disease and the controversial use of estrogen therapy Biol Sex Differ 8 33-8
[7]  
Chen W(1996)Risk factors for cardiovascular disease in women: assessment and management Eur Heart J 17 2-e13
[8]  
Zheng R(2021)Evidence-based approaches for the management of side-effects of adjuvant endocrine therapy in patients with breast cancer Lancet Oncol 22 e303-301
[9]  
Baade PD(2011)Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: a retrospective cohort study Breast Cancer Res 13 R64-204
[10]  
Zhang S(2021)Effects of tamoxifen vs. toremifene on fatty liver development and lipid profiles in breast Cancer BMC Cancer 21 798-55